Patient Square Capital is a dedicated health care investment firm that will make outstanding investments by partnering with best-in-class management teams whose products, services and technologies improve health.
Patient Square leverages its deep and established network to seek opportunities to deploy capital in companies across the broad health care industry with targets including biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, technology-enabled services, digital and consumer health sectors.
Patient Square leverages its deep and established network to seek opportunities to deploy capital in companies across the broad health care industry with targets including biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, technology-enabled services, digital and consumer health sectors.
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2020
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 24.10.2022 | Resolve Bi... | resolvebiosciences.com | $71M | Germany, B... |
| 14.07.2021 | Kriya Ther... | kriyatx.com | $100M | United Sta... |
News 13
| Date | Title | Description |
| 06.04.2022 | SOC Telemed Completes Acquisition by Patient Square Capital | - |
| 06.04.2022 | SOC Telemed | PSC – Investing to Grow the Leading Acute Care Telemedicine Company | - |
| 03.02.2022 | SOC Telemed to be Acquired by Patient Square Capital | Herndon, VA – February 3, 2022 – SOC Telemed, Inc. (NASDAQ: TLMD) (the “Company” or “SOC Telemed”), the largest national provider of acute care telemedicine, today announced that it has entered into a definitive agreement to be acquired by ... |
| 24.11.2021 | Patient Square Capital Closes Acquisition of Summit BHC | FRANKLIN, TN, November 24, 2021 – Patient Square Capital, a dedicated health care investment firm, today announced the closing of its previously announced acquisition of Summit BHC (“Summit” or “the Company”), a leading provider of behavior... |
| 09.09.2021 | - | Transaction Positions Innovative Provider of Behavioral Health Treatment for Next Chapter of Success |
| 14.07.2021 | Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies | Financing led by Patient Square Capital with participation from leading life sciences investors to support the further development of Kriya’s core technology platforms, advancement of its current programs and continued expansion of its pipe... |
| 17.06.2021 | - | Proceeds to support rapid advancement of pipeline with over 15 therapeutic programs currently in development across oncology, major inflammatory disorders and rare disease |
| 20.04.2021 | - | MENLO PARK, CA, April 20, 2021 – Patient Square Capital, a dedicated health care investment firm, announced today that Jake Cabala has joined as a Partner, where he will be the Head of Fund Partnerships and primarily be responsible for the ... |
| 06.04.2021 | - | MENLO PARK, CA, April 6, 2021 – Patient Square Capital, a dedicated health care investment firm, announced today that it has established a proprietary research and due diligence center of excellence called Patient Square Insights (“PSI”). P... |
| 23.03.2021 | - | MENLO PARK, CA, March 23, 2021 – Patient Square Capital, a dedicated health care investment firm, announced today that Karr Narula has joined as Founding Partner. Prior to joining Patient Square, Mr. Narula spent 13 years at KKR, where he w... |
Show more
Mentions in press and media 27
| Date | Title | Description |
| 09.09.2026 | Elucid Secures $55M to Revolutionize Heart Diagnostics with AI | Elucid, a Boston-based medtech innovator, just secured $55M in an oversubscribed Series D funding. Total capital now reaches $185M. The company pioneers AI-powered software for precision cardiovascular diagnosis and treatment. Funds will ac... |
| 03.09.2026 | Elucid Scores $55M Series D Round | BOSTON, MA, Elucid has announced the raise of $55 million in an oversubscribed Series D financing. >> Click here for more funding data on Elucid >> To export Elucid funding data to PDF and Excel, click here Elucid, a medical te... |
| 02.09.2026 | Elucid Raises $55M to Expand AI Cardiovascular Diagnostics | Elucid Raises $55M Series D Funding Boston-based medical technology company Elucid has raised $55 million in fresh funding. The company secured the capital through an oversubscribed Series D financing round. The round brings its total fundi... |
| 23.06.2026 | Osanni Bio Raises $190M in Series B Funding | Osanni Bio, a San Francisco, CA-based provider of a development-stage therapeutics platform, raised $190M in Series B funding. The round was led by Patient Square Capital with participation from the Horowitz Group, Invus Opportunities, and ... |
| 21.03.2026 | Imperative Care Secures $100M: Revolutionizing Stroke and Vascular Treatment | Imperative Care raised $100M, accelerating innovation in stroke and vascular care. This funding propels commercialization of successful thrombectomy systems—Zoom, Symphony, Prodigy—already used in over 78,000 global procedures. Crucially, i... |
| 19.03.2026 | Imperative Care Secures $100M to Automate Stroke Treatment, Develop Endovascular Robotics Platform | What You Should Know The Financing: Imperative Care, a commercial-stage medical technology company, has closed an oversubscribed $100M convertible note financing round. The Investors: The round was co-led by new investors Elevage Medical Te... |
| 14.01.2026 | Nuclera Accelerates AI-Driven Antibody Engineering with $87 Million Capital Infusion | Nuclera secures an additional $12 million, elevating Series C funding to $87 million. This critical capital fuels accelerated antibody engineering on its eProtein Discovery benchtop system. The biotech leader targets AI-enabled protein deve... |
| 13.01.2026 | Nuclera extends Series C funding to $87M to accelerate antibody engineering work | Biotech company Nuclera has secured an additional $12 million in financing, bringing its total Series C funding to $87 million. The extension was led by Elevage Medical Technologies and Jonathan Milner, with participation from existing inve... |
| 05.11.2025 | Braveheart Bio Raises $185M in Series A Funding | Braveheart Bio, a San Francisco, CA-based clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, raised $185M in Series A financing. Backers included Andreessen Horow... |
| 22.09.2025 | Patient Square Capital Acquires Premier in $2.6B Deal | What You Should Know: – Premier, Inc., a healthcare improvement company, has announced a definitive agreement to be acquired by an affiliate of Patient Square Capital. – Under the terms of the agreement, Premier stockholders will receive $2... |
Show more